
pmid: 9658375
Two batches of a new hepatitis A/hepatitis B combined vaccine were tested in 242 healthy students. Three injections, given at 0, 1 and 6 months, produced seroconversion rates and hepatitis A virus (HAV) and hepatitis B surface antigen (HBsAg) antibody levels comparable to those reported after administration of separate monocomponent vaccines. The vaccine proved to be safe and well‐tolerated. Influence of host factors, such as elevated body mass index or gender, were investigated and proven to be of little influence on the immunoresponse.
Adult, Male, Viral Hepatitis Vaccines, Hepatitis A Vaccines, Vaccines, Synthetic, Hepatitis B Surface Antigens, Vaccination, Hepatitis A Antibodies, Humans, Female, Hepatitis B Vaccines, Hepatitis Antibodies, Vaccines, Combined, Hepatitis B Antibodies, Hepatitis A Virus, Human
Adult, Male, Viral Hepatitis Vaccines, Hepatitis A Vaccines, Vaccines, Synthetic, Hepatitis B Surface Antigens, Vaccination, Hepatitis A Antibodies, Humans, Female, Hepatitis B Vaccines, Hepatitis Antibodies, Vaccines, Combined, Hepatitis B Antibodies, Hepatitis A Virus, Human
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 22 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
